This blog explores the vital role of lung cancer clinical trials in providing patients with early access to innovative treatments and offering key insights that drive medical progress. At Lambda Therapeutic Research, we’re honored to partner with global biotech and pharmaceutical leaders to support these life-changing studies, working together for a future with better outcomes for cancer patients.
Lung Cancer Awareness Month
November is Lung Cancer Awareness Month. According to the latest global estimates from the International Agency for Research on Cancer (IARC), nearly 2.5 million people were diagnosed with lung cancer in 2022, and over 1.8 million died from the disease. The primary risk factor for developing lung cancer remains tobacco smoking, responsible for approximately 85% of all cases, as reported by the World Health Organization (WHO). Other common causes include exposure to contaminants such as second-hand tobacco smoke, outdoor and indoor air pollution, diesel engine exhaust, welding fumes, and asbestos.
As one of the most challenging cancers to treat, lung cancer affects millions worldwide, and each year brings new insights and progress. Clinical trials are a crucial part of this journey, offering patients access to promising therapies while helping researchers gather vital information on safety and effectiveness.
A Closer Look at Lung Cancer Clinical Trials
Clinical trials are essential for expanding our knowledge of lung cancer and advancing more effective treatments. For patients, these trials often provide access to innovative therapies that may not yet be available outside the study setting. For researchers and healthcare providers, clinical trials enable the refinement of existing treatments and the discovery of new options, building a foundation of hope and progress for those affected by lung cancer.
Important areas of interest for new therapeutic development in lung cancer are cell therapy and gene therapy. A number of companies and academic institutions are now pursuing the development of such advanced treatments.
Advances in Small Cell Lung Cancer (SCLC) Treatment — After more than 50 years without significant advancements, patients with limited-stage SCLC now have a new treatment option that goes beyond surgery, radiation, and chemotherapy. Data from the ADRIATIC study showed that, following chemotherapy and radiation for inoperable limited-stage SCLC, immunotherapy (durvalumab) can help keep the cancer at bay.
Researchers have made tremendous strides in treating non-small cell lung cancer (NSCLC) over the past 20 years, largely due to the development of biomarkers and targeted therapies. Recent data suggest that additional biomarkers, such as fibroblast growth factor receptor (FGFR) alterations and mesenchymal-epithelial transition factor (cMet) overexpression, may soon become available for patients with advanced NSCLC. This progress is promising, as new biomarkers are likely to open the door to more personalized treatment options.
Oncology Excellence: A Proven Track Record
At Lambda & Novum, our commitment to advancing cancer treatment is reflected in our extensive experience in oncology clinical trials. With a strong portfolio that includes over 265 clinical trials spanning 15+ therapeutic areas, oncology remains a cornerstone of our expertise.
65+
Oncology Trials
6000+
Patients
900+
Global Sites
We have supported over 65 clinical trials, specifically targeting various cancer indications including Non-Small Cell Lung Cancer (NSCLC). Our end-to-end capabilities—ranging from medical imaging to pharmacovigilance, biostatistics, and bioanalytical services—enable us to deliver comprehensive solutions for our clients. By ensuring high standards of quality and regulatory compliance, we consistently achieve robust, reliable results in lung cancer clinical trials. Our successful regulatory submissions to the USFDA, EMA, and ANVISA underscore our deep understanding of global regulatory frameworks and our proficiency in navigating the complexities of the approval process.
Optimizing Lung Cancer Clinical Trials:
Strategic Site Selection
Selecting the right clinical trial sites is crucial for the success of lung cancer clinical trials. We prioritize this process, focusing on experienced investigators and site staff well-versed in clinical oncology, especially in managing lung cancer. These carefully chosen sites ensure optimal data collection and a smoother trial experience for recruited patients.
Streamlining Recruitment & Retention
Enhancing trial success, we employ patient-centric initiatives and care coordinators, addressing barriers for a supportive participant experience. Recruitment and retention challenges are effectively tackled through these coordinators’ close work with participants, leading to improved patient outcomes and better data collection.
Innovative Trial Protocols
Innovation is at the heart of our trial protocols, ensuring a patient-centric experience. We design innovative and patient-friendly protocols that enhance the trial journey. By incorporating the latest advancements and considering the unique needs of lung cancer patients, we strive for improved outcomes and seamless data collection.
Transform Your Oncology Trials with Our Proven Expertise
Explore Our Success Stories:
Leverage Lambda & Novum’s extensive experience & proven track record to accelerate your Oncology clinical trials. Get in touch with our team of experts.
About Lambda
Lambda & Novum delivers full-service CRO services to the innovator, biotech, and generic pharmaceutical industries worldwide. With a strong global presence in India, the USA, Canada, the UK, Spain and Poland, we bring specialized expertise to every project. Our focus on secure IT infrastructure and automation ensures timely project delivery and strict adherence to international regulatory standards. Lambda’s exemplary regulatory track record includes over 60 successful inspections and audits by esteemed authorities, including the USFDA, EMEA, MHRA, EU member states, and other global regulatory bodies, in the past five years.
Lambda’s commitment to excellence has garnered significant recognition, including the ‘Best Indian CRO’ award from Frost & Sullivan (USA) and the ‘Great Indian Workplace’ title from UBS Transformance. Recent accolades include the ‘Regulatory Excellence’ Award at the CPhI Pharma Awards 2023 and the ‘Industry Partner of the Year’ Award at the Global Generics & Biosimilar Awards 2023.
